PHARMA LITERATI

Lupin Ltd. on Monday announced a partnership with global pharmaceutical giant AbbVie for the development and commercialisation of its novel oncology drug to treat hematological cancers. AbbVie has entered into a licensing agreement with Lupin for its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor programme and taken the responsibility for further development and launch of the drug in the market. Through this partnership, AbbVie has gained exclusive global rights to develop and commercialise Lupin’s MALT1 inhibitors. Under the terms of the agreement, AbbVie would give Lupin an upfront payment of $30 million for an exclusive licence to the programme. Upon successful completion of regulatory, development and commercial milestones, Lupin is eligible to receive total milestone payments of up to $947 million. Double-digit royalty Additionally, Lupin will be entitled to receive a double-digit royalty on sales of the product and r

Controlled Release Society Indian Chapter organises 17 th  International Symposium on Advances in Technology and Business Potential of New Drug Delivery Systems Date: 1 st  & 2 nd  February, 2019. Venue:  The Lalit, Sahar Airport Road,  Andheri (East), Mumbai 400059. Brochure available at:  http://www.crsic.org/pdf/CRSIC-FIRST-ANNOUNCEMENT-FEB-2019-Intnl-Symp-FINAL-250518.pdf

Register for the courses at: https://docs.google.com/forms/d/1UodZCPFiJUc0GkdnQ7DJiXFbeavsaOq8iby0cvt5hgk/viewform?edit_requested=true

Indians can’t purchase medicines online legally anymore. On Dec.12, the Delhi high court ordered a complete ban on online pharmacies across the country with immediate effect, asking the central government to implement the order. The court order is in response to a petition which stated that the sale of drugs and prescription medicines online was illegal and without any mandate of law and, therefore, a health risk: Unlike common items, drugs are highly potent and its misuse or abuse can have serious consequences on human health, not just for the one person consuming it but for humanity at large as some drugs can be addictive, habit-forming and harmful to the body. A large number of children/minor or people from uneducated rural background use the internet and can be victims of wrong medication while ordering medicines online. India’s pharmacy laws are derived from the Drugs and Cosmetics Act, 1940, Drugs and Cosmetics Rule, 1945, and the Pharmacy Act, 1948. These laws

Job opening for a life sciences' service provider startup based in Navi Mumbai. Qualifications: B. Pharm/ M. Pharm/ MBA. Location: Navi Mumbai, Turbhe. Salary: 15k to 18k per month based on experience and qualification. Job Profile: 1. Digital marketing, content writing. 2. Generating competitive intelligence reports. 3. Client visits (Once a week, if required). 4. Market research. Detailed profile would be shared during the interview. Kindly send your CV to  pharmaliterati@gmail.com

Call it opportunistic volume gain at better margins or seeking new growth options under adverse market conditions. Either way, some of the leading Indian pharma companies are pitching in to cater to the markets that some of the big global pharma companies are vacating as part of their product optimisation strategies. They are also pitching in to fill in for the temporary shortages that some of the companies have caused due to issues such as regulatory challenges their plants face. Agile companies that can meet this gap and in turn expand their market share see this as an opportunity. One such company is Hyderabad-based Aurobindo Pharma , which has even given it a name 'New Business Opportunity'. The move, apparently, is yielding results. Aurobindo has received an opportunity to supply an incremental volume worth $90 million to $100 million over a span of 12 to 15 months starting second quarter of FY18. In fact, the company has also been building capacities so that i